This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Alert me on articles by topic

Associations With Medication and Medical Utilization and Spending and Health

Dana P. Goldman, PhD; Geoffrey F. Joyce, PhD; Yuhui Zheng, MPhil

JAMA. 2007;298:61-69.

Context  Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them.

Objective  To synthesize published evidence on the associations among cost-sharing features of prescription drug benefits and use of prescription drugs, use of nonpharmaceutical services, and health outcomes.

Data Sources  We searched PubMed for studies published in English between 1985 and 2006.

Study Selection and Data Extraction  Among 923 articles found in the search, we identified 132 articles examining the associations between prescription drug plan cost-containment measures, including co-payments, tiering, or coinsurance (n = 65), pharmacy benefit caps or monthly prescription limits (n = 11), formulary restrictions (n = 41), and reference pricing (n = 16), and salient outcomes, including pharmacy utilization and spending, medical care utilization and spending, and health outcomes.

Results  Increased cost sharing is associated with lower rates of drug treatment, worse adherence among existing users, and more frequent discontinuation of therapy. For each 10% increase in cost sharing, prescription drug spending decreases by 2% to 6%, depending on class of drug and condition of the patient. The reduction in use associated with a benefit cap, which limits either the coverage amount or the number of covered prescriptions, is consistent with other cost-sharing features. For some chronic conditions, higher cost sharing is associated with increased use of medical services, at least for patients with congestive heart failure, lipid disorders, diabetes, and schizophrenia. While low-income groups may be more sensitive to increased cost sharing, there is little evidence to support this contention.

Conclusions  Pharmacy benefit design represents an important public health tool for improving patient treatment and adherence. While increased cost sharing is highly correlated with reductions in pharmacy use, the long-term consequences of benefit changes on health are still uncertain.

Author Affiliations: Health Economics, Finance, and Organization (Drs Goldman and Joyce) and Pardee RAND Graduate School (Ms Zheng), RAND, Santa Monica, California.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Medicaid Prescription Formulary Restrictions and Arthritis Treatment Costs
Johnson and Stahl-Moncada
Am. J. Public Health 2008;98:1300-1305.
ABSTRACT | FULL TEXT  

Beyond The Efficiency Index: Finding A Better Way To Reduce Overuse And Increase Efficiency In Physician Care
Greene et al.
Health Aff (Millwood) 2008;27:w250-w259.
ABSTRACT | FULL TEXT  

Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making
Rosenheck et al.
Psychiatr. Serv. 2008;59:515-520.
ABSTRACT | FULL TEXT  

Model for medication therapy management in a university clinic
Kliethermes et al.
Am J Health Syst Pharm 2008;65:844-856.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post-Myocardial Infarction Medicare Beneficiaries
Choudhry et al.
Circulation 2008;117:1261-1268.
ABSTRACT | FULL TEXT  

France's health care system
Dhalla and Thomson
CMAJ 2008;178:596-596.
FULL TEXT  

Impact Of Decreasing Copayments On Medication Adherence Within A Disease Management Environment
Chernew et al.
Health Aff (Millwood) 2008;27:103-112.
ABSTRACT | FULL TEXT